Andere Sprachen Mabwell (Shanghai) Bioscience Co., Ltd.

Aktien

688062

CNE100005RD2

688062

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 13.06.2024			% 5 Tage	% 1. Jan.
33,35 ^CNY	+1,68 %		+4,19 %	+2,02 %

24.05.	Mabwell gibt klinische Daten zu 9MW2821 bekannt	CI
13.05.	Mabwell gibt den Fortschritt der klinischen Studie von 9MW2821 bei dreifach negativem Brustkrebs bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Mabwell Announces 9MW2821 Clinical Data	24.05.
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer	13.05.
Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821	07.05.
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
Mabwell Announces MAIWEIJIAN, First Approved Biosimilar of Denosumab in China	08.04.
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08.04.
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment	04.04.
Mabwell Presents Clinical Study Data of the 9MW2821 for Patients with Cervical Cancer as Focused Plenary Oral Presentation At the Society of Gynecologic Oncology Annual Meeting	19.03.
Mabwell Scraps Licensing Deal With Yangtze River Pharma	27.02.
Mabwell Publishes Phase III Study Results of Denosumab Biosimilar in the International Top Journal of Jama Oncology	21.02.
Mabwell Receives IND Approval from FDA for Novel B7-H3 ADC 7Mw3711	20.02.
Mabwell Shanghai Bioscience Gets US FDA's Nod to Trial on Tumor Drug; Shares Jump 5%	19.02.
Certain A-Shares of Mabwell Bioscience Co., Ltd. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.	18.01.
National Medical Products Administration Accepts Mabwell's 8MW0511 for Injection Accepted by NMPA	19.12.
Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting Adc for Phase III Clinical Trial	11.12.
Mabwell Shanghai Bioscience Gets Nod to Trial Urothelial Cancer Drug	08.12.
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs	23.10.23
Mabwell Bioscience Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	18.10.23
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor	28.09.23
Mabwell Bioscience Co., Ltd.(XSSC:688062) added to S&P Global BMI Index	18.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mabwell (Shanghai) Bioscience Co., Ltd.

Aktien

688062

CNE100005RD2

688062

Andere Sprachen

Filter